02.07.2012 - Cell cultivation company Vitrolife announced it will acquire Hungarian Cryo Management Ltd, a specialist in time-lapse embryo monitoring for IVF.
Gothenburg – The purchase sum is €5m, and could be increased to €9m upon the fulfilment of defined objectives primarily related to sales during the period 2013 to 2015. Through the acquisition, Vitrolife gains access to a product portfolio in the form of time-lapse products for IVF and increased knowledge within IVF technology and embryo development.
The fixed purchase sum is financed by a corporate acquisition loan of €3m and by payment of €2m in newly issued shares or cash. If payment is in shares, this is planned to be carried out after distribution of the subsidiary Xvivo Perfusion AB. Vitrolife, headquartered in Gothenburg in Sweden, anticipates that the acquisition will have a marginally negative effect on earnings per share for 2012 due to increased marketing activities and transaction expenses but that the business will make a positive contribution as from 2013. Cryo Management Ltd and its subsidiary Cryo Innovation Ltd are located in Budapest, Hungary. The company was formed in 2005, with 20 employees and budgeted sales of approximately €2m for 2012. The company has developed, produced and marketed time-lapse products, primarily for the IVF market. Its Primo Vision time-lapse technology takes images of the embryos at short intervals during the cultivation process. The pictures are then played back as a film which is analysed by an embryologist. This method avoids, amongst other things, today’s problem that the sensitive embryo is subjected to stress when being evaluated as the embryo must be taken out of the incubator for assessment. The time-lapse technology also enables the entire development of the embryo to be studied, which gives greater opportunities to choose the most optimal embryo and thereby improve the chances of pregnancy.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.